Encephale
-
Randomized Controlled Trial Multicenter Study Comparative Study
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Several recent studies have underlined the importance of anxiety in major depressive disorders. It has been shown that anxiety was responsible for worsening of depression and reduction of the efficacy of the antidepressant treatment. While it is well known that SSRI are efficient in treating depression or anxiety disorders, the authors tried to determine the influence of baseline anxiety on the response to SSRI treatment in patients with severe depression receiving either escitalopram or paroxetine. ⋯ As far as complete remitters (CGI-S=1) after 24-week treatment were concerned, their number was significantly higher with escitalopram in the case of marked baseline anxiety. No difference was shown in the low baseline anxiety group. Looking for the influence of baseline anxiety on SSRI treatment effects, the authors showed that antidepressant efficacy of 20mg escitalopram was better than 40mg paroxetine for patients highly depressed with comorbid anxiety symptoms and that, contrary to paroxetine, escitalopram maintained sustained antidepressant activity in patients featuring increased baseline anxiety levels.
-
Comparative Study
[The Alexithymia Questionnaire for Children (AQC): French translation and validation study in a convenience sample of 80 children].
Alexithymia refers to a specific disturbance in psychic functioning characterized by a limited ability to identify and communicate one's feelings. Development of specific rating scales and notably the well-validated 20-item Toronto alexithymia Scale (TAS-20) have allowed the study of alexithymia in numerous samples of clinical or non-clinical subjects. Recently, Rieffe et al. [Pers and Individ Differ 40 (2006) 123-133] have developed an alexithymia questionnaire for children (AQC) basing on the TAS-20. The AQC comprised 20 items divided into three subscales: difficulty-identifying feelings (DIF), difficulty describing feelings (DDF) and externally-oriented thinking (EOT). Using a sample of 740 children and the Dutch version of the AQC the three-factor structure of alexithymia was found, using confirmatory factorial analysis, but the EOT factor showed low factor loadings and reliability. ⋯ The three-factor model of the AQC was reported for the French version of scale but the EOT factor had low validity. This result confirms the recent study using the Dutch version of the AQC. Moreover, several studies using foreign versions of the TAS-20 reported low reliability of the EOT factor. Thus, other studies are necessary to explore the reliability of the EOT factor of the French version of the AQC, and it's recommended to use only the total score of the AQC instead of the sub-scores.
-
Few studies have been devoted to in-patients' suicides. This covers all suicides that occurred during hospitalisation, whatever the place (inside or outside the institution) and often, for psychiatric in-patients, suicides carried out within 24 hours after leaving the institution. ⋯ However, the incidence of suicide in hospital is high, higher than that observed in the general population. It is 250 per 100,000 admissions in psychiatric hospitals and 1.8 per 100,000 admissions in general hospitals, which is four to five times more than in general population. Five to 6.5% of suicides are committed in the hospital: 3 to 5.5% occur in psychiatric hospitals and about 2% in general hospitals. Many risk factors for suicide were identified in this context. The accessibility to one or more means of suicide (water, rail, high floor [third floor or beyond], knives, possibility of hanging...) is a recognized factor in psychiatric institutions. In the psychiatric environment, hospitalisation period also determines the risk of suicide: it is highest during the 1st week of hospitalisation and within 2 weeks after leaving. The same is true for the conditions of care: inadequate supervision, the underestimation of the risk of suicide by teams, poor communication within the teams and the lack of intensive care unit promote suicide risk. The controlled studies conducted in a psychiatric environment distinguish two periods for identifying risk factors. The first period is the time of hospitalisation. Are recognized as risk factors: the existence of suicidal personal history (but also family) and attempted suicide shortly before admission, the diagnosis of schizophrenia or mood disorder (non-controlled studies also emphasize the importance of alcoholic comorbidity), being hospitalised without consent, living alone, absence from the service without permission. The second period covers the time-period immediately following the hospitalisation. For this period, risk factors are: the existence of personal history of suicide and suicidal ideation or attempt of suicide shortly before admission (but also attempt of suicide during hospitalisation), the existence of relational difficulties, the existence of stress or loss of employment, living alone, a decision on leaving the hospital unplanned and lack of contact with nursing in the immediate postdischarge period. In general hospitals, the chronicity and severity of the somatic disease, the personality of the patient and the existence of a psychiatric comorbidity are the suicidal factors most often quoted. Furthermore, we also found only a low rate of psychiatric consultation during the hospitalisation of patient who will commit suicide. Among the countries which have a national program of suicide prevention, only England registered the question of the in-patients suicide among its priorities. The elements of a prevention policy appear however in certain scientific publications and some programs of local or regional initiative. These elements can be grouped under five items: securing the hospital environment, optimisation of the care of the patients at suicidal risk, training of the medical teams in the detection of the risk and in the care of the suicidal subjects, involvement of the families in the care and implementation of post-event procedures following a completed suicide or an attempt.
-
Controlled Clinical Trial
[Long-term impact of the diagnostic announcement on the insight of patients suffering from schizophrenic disorders].
The importance of insight in patients with schizophrenia is linked to the notion that few subjects are conscious of their pathology and that some treatments fail due to a lack of consciousness of the necessity of medication. Since then, studies have been frequently undertaken into the insight of schizophrenic patients. It is believed that a good degree of insight could influence the quality of acceptance by the patient of the disease. This would facilitate closer medicinal supervision, resulting in fewer relapses and thus a decrease in the number of hospitalizations and subsequent improved quality of life for the patients. In 2002, a protocol of diagnostic announcement was set up for schizophrenic patients in the Ville-Evrard Hospital. Two years later, we observed a high level of compliance in these patients (70 %). ⋯ In conclusion, the protocol of diagnostic announcement and psycho-education have helped stabilize schizophrenic patients in order to improve their insight, without increasing the intensity of this disease in the short- or long-term. Work on insight should allow a new understanding of the patient's relation with the disease along with the medical team and his close relations.
-
Case Reports
[Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report].
We report a case of serotonin syndrome caused by interaction between nasal fentanyl, oxycodone and escitalopram. Due to chronic painful episodes with paroxistic level of pain, a 66-year-old patient, treated for prostate adenocarcinoma and bone metastases received an association of major opiate analgesics (oxycodone 120 mg/day for 6 months, and fentanyl nasal spray four puff of 200 microg/puff). After the addition, for mood disorders, of a small dose of escitalopram (5 mg/day), he developed severe serotoninergic features including diaphoresis, night sweating, tremor, diarrhea, visual disorders with mydriasis and weight loss of 8.8 lbs (4 kg). Discontinuation of escitalopram resulted in complete resolution of his symptoms within 48 h except for persistent blurred vision. ⋯ Clinicians and especially psychiatrists should be aware of possible interaction and the risk of serotonin syndrome when a patient receives a combination of different opioid analgesics and serotonin reuptake inhibitor antidepressants. Improved information and collaboration with somatic and pain specialists and the general practitioners could help reduce the occurrence of this syndrome which can have dreadful consequences. Patients must be informed of such complications, which means that patients should be asked for a history of such events and monitored for serotoninergic adverse events, in order to avoid delays in this diagnosis.